Advertisement
Research Article Free access | 10.1172/JCI119362
Medicine Branch, DCS, NCI, Bethesda, Maryland 20892, USA.
Find articles by Mickley, L. in: JCI | PubMed | Google Scholar
Medicine Branch, DCS, NCI, Bethesda, Maryland 20892, USA.
Find articles by Spengler, B. in: JCI | PubMed | Google Scholar
Medicine Branch, DCS, NCI, Bethesda, Maryland 20892, USA.
Find articles by Knutsen, T. in: JCI | PubMed | Google Scholar
Medicine Branch, DCS, NCI, Bethesda, Maryland 20892, USA.
Find articles by Biedler, J. in: JCI | PubMed | Google Scholar
Medicine Branch, DCS, NCI, Bethesda, Maryland 20892, USA.
Find articles by Fojo, T. in: JCI | PubMed | Google Scholar
Published April 15, 1997 - More info
Drug resistance, a major obstacle to cancer chemotherapy, can be mediated by MDR-1/P-glycoprotein. Deletion of the first 68 residues of MDR-1 in an adriamycin-selected cell line after a 4;7 translocation, t(4q;7q), resulted in a hybrid mRNA containing sequences from both MDR-1 and a novel chromosome 4 gene. Further selection resulted in amplification of a hybrid gene. Expression of the hybrid mRNA was controlled by the chromosome 4 gene, providing a model for overexpression of MDR-1. Additional hybrid mRNAs in other drug-selected cell lines and in patients with refractory leukemia, with MDR-1 juxtaposed 3' to an active gene, establishes random chromosomal rearrangements with overexpression of hybrid MDR-1 mRNAs as a mechanism of acquired drug resistance.